Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.58 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59048 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL15435038 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL58338 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL13682227 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL59676 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL15435013 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL59693 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL59443 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL89669 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL60266 | 1.00 | TUBB1 (0.58) | TUBB1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881829-A2 | UNSOLVATED AND HOST-GUEST SOLVATED CRYSTALLINE FORMS OF (2E,4S)-4-[(N-{[(2R)-1-ISOPROPYLPIPERIDIN-2-YL]-CARBONYL}-3-METHYL-L-VALYL)(METHYL)AMINO]-2,5-DIMETHYLHEX-2-ENOIC ACID AND THEIR PHARMACEUTICAL USES | Eisai Co., Ltd. (JP) | 2008-01-30 | — | — | EP | claimed |
| US-20060281690-A1 | Crystalline (2E,4S)-4-[(N-{[(2R)-1-isopropylpiperidin-2-yI]-carbonyl}-3-methyl-L-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and its pharmaceutical uses | EISAI CO. LTD. (JP) | 2006-12-14 | — | — | US | claimed |
| WO-2006121857-A2 | UNSOLVATED AND HOST-GUEST SOLVATED CRYSTALLINE FORMS OF (2E,4S)-4-[(N-{[(2R)-1-ISOPROPYLPIPERIDIN-2-YL]-CARBONYL}-3-METHYL-L-VALYL)(METHYL)AMINO]-2,5-DIMETHYLHEX-2-ENOIC ACID AND THEIR PHARMACEUTICAL USES | EISAI CO., LTD. (JP) | 2006-11-16 | — | — | WO | claimed |
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS BC INC. (CA) | 2023-08-24 | — | — | US | disclosed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | disclosed |
| EP-3086815-B1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS INC (CA) | 2022-02-09 | — | — | EP | disclosed |
| EP-3087091-B1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC (CA) | 2021-10-20 | — | — | EP | disclosed |
| US-10675355-B2 | VAR2CSA-drug conjugates | VAR2 PHARMACEUTICALS APS (DK) | 2020-06-09 | — | — | US | disclosed |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2018-05-03 | — | — | US | disclosed |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-20170029490-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-02-02 | — | — | US | disclosed |
| CN-101189013-A | Crystalline (2E,4S)-4-[(N-{[(2R)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-L-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and its pharmaceutical uses | EISAI CO LTD (JP) | 2008-05-28 | — | — | CN | disclosed |
| EP-1881829-A2 | UNSOLVATED AND HOST-GUEST SOLVATED CRYSTALLINE FORMS OF (2E,4S)-4-[(N-{[(2R)-1-ISOPROPYLPIPERIDIN-2-YL]-CARBONYL}-3-METHYL-L-VALYL)(METHYL)AMINO]-2,5-DIMETHYLHEX-2-ENOIC ACID AND THEIR PHARMACEUTICAL USES | Eisai Co., Ltd. (JP) | 2008-01-30 | — | — | EP | disclosed |
| EP-1881829-A2 | UNSOLVATED AND HOST-GUEST SOLVATED CRYSTALLINE FORMS OF (2E,4S)-4-[(N-{[(2R)-1-ISOPROPYLPIPERIDIN-2-YL]-CARBONYL}-3-METHYL-L-VALYL)(METHYL)AMINO]-2,5-DIMETHYLHEX-2-ENOIC ACID AND THEIR PHARMACEUTICAL USES | Eisai Co., Ltd. (JP) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006121857-A3 | UNSOLVATED AND HOST-GUEST SOLVATED CRYSTALLINE FORMS OF (2E,4S)-4-[(N-{[(2R)-1-ISOPROPYLPIPERIDIN-2-YL]-CARBONYL}-3-METHYL-L-VALYL)(METHYL)AMINO]-2,5-DIMETHYLHEX-2-ENOIC ACID AND THEIR PHARMACEUTICAL USES | EISAI CO LTD (JP) | 2007-07-26 | — | — | WO | disclosed |
| US-20060281690-A1 | Crystalline (2E,4S)-4-[(N-{[(2R)-1-isopropylpiperidin-2-yI]-carbonyl}-3-methyl-L-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and its pharmaceutical uses | EISAI CO. LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| US-20060281690-A1 | Crystalline (2E,4S)-4-[(N-{[(2R)-1-isopropylpiperidin-2-yI]-carbonyl}-3-methyl-L-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and its pharmaceutical uses | EISAI CO. LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| US-20060281690-A1 | Crystalline (2E,4S)-4-[(N-{[(2R)-1-isopropylpiperidin-2-yI]-carbonyl}-3-methyl-L-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and its pharmaceutical uses | EISAI CO. LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| WO-2006121857-A2 | UNSOLVATED AND HOST-GUEST SOLVATED CRYSTALLINE FORMS OF (2E,4S)-4-[(N-{[(2R)-1-ISOPROPYLPIPERIDIN-2-YL]-CARBONYL}-3-METHYL-L-VALYL)(METHYL)AMINO]-2,5-DIMETHYLHEX-2-ENOIC ACID AND THEIR PHARMACEUTICAL USES | EISAI CO., LTD. (JP) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121857-A2 | UNSOLVATED AND HOST-GUEST SOLVATED CRYSTALLINE FORMS OF (2E,4S)-4-[(N-{[(2R)-1-ISOPROPYLPIPERIDIN-2-YL]-CARBONYL}-3-METHYL-L-VALYL)(METHYL)AMINO]-2,5-DIMETHYLHEX-2-ENOIC ACID AND THEIR PHARMACEUTICAL USES | EISAI CO., LTD. (JP) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | TUBB1 516/4885ELANE 3483/4885 |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | TUBB1 216/4885ELANE 1756/4885 |
| US-10675355-B2 | VAR2CSA-drug conjugates | VARS1, GUSB, VAV1 | TUBB1 216/4885ELANE 1756/4885 |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | TUBB1 216/4885ELANE 1756/4885 |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | MPST, TPST2, SULT1A1 | TUBB1 516/4885ELANE 3483/4885 |
| US-20060281690-A1 | Crystalline (2E,4S)-4-[(N-{[(2R)-1-isopropylpiperidin-2-yI]-carbonyl}-3-methyl-L-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and its pharmaceutical uses | UACA, MALT1, LY96 | TUBB1 3903/4885ELANE 2732/4885 |
| US-20170029490-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | TUBB1 516/4885ELANE 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.